Regulatory T-cell development in the human thymus by Caramalho, Íris et al.
August 2015 | Volume 6 | Article 3951
Mini Review
published: 03 August 2015
doi: 10.3389/fimmu.2015.00395
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Geraldo Aleixo Passos, 
University of São Paulo, Brazil
Reviewed by: 
Sylvie Lesage, 
University of Montreal and 
Maisonneuve-Rosemont Hospital, 
Canada 
Alberto Varas, 
Complutense University, Spain
*Correspondence:
 Ana E. Sousa, 
Instituto de Medicina Molecular, 
Faculdade de Medicina, Universidade 
de Lisboa, Avenue Prof Egas Moniz, 
1649-028 Lisbon, Portugal 
asousa@medicina.ulisboa.pt
†Co-first authors.
Specialty section: 
This article was submitted to 
Immunological Tolerance, a section of 
the journal Frontiers in Immunology
Received: 22 June 2015
Accepted: 19 July 2015
Published: 03 August 2015
Citation: 
Caramalho Í, Nunes-Cabaço H, 
Foxall RB and Sousa AE (2015) 
Regulatory T-cell development 
in the human thymus. 
Front. Immunol. 6:395. 
doi: 10.3389/fimmu.2015.00395
Regulatory T-cell development in the 
human thymus
Íris Caramalho †, Helena Nunes-Cabaço †, Russell B. Foxall  and Ana E. Sousa *
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
The thymus generates a lineage-committed subset of regulatory T-cells (Tregs), best 
identified by the expression of the transcription factor FOXP3. The development of thy-
mus-derived Tregs is known to require high-avidity interaction with MHC-self peptides 
leading to the generation of self-reactive Tregs fundamental for the maintenance of 
self-tolerance. Notwithstanding their crucial role in the control of immune responses, 
human thymic Treg differentiation remains poorly understood. In this mini-review, we will 
focus on the developmental stages at which Treg lineage commitment occurs, and their 
spatial localization in the human thymus, reviewing the molecular requirements, including 
T-cell receptor and cytokine signaling, as well as the cellular interactions involved. An 
overview of the impact of described thymic defects on the Treg compartment will be 
provided, illustrating the importance of these in vivo models to investigate human Treg 
development.
Keywords: human thymus, regulatory T-cells, FOXP3, regulatory T-cell development, human thymic defects, 
primary immunodeficiency
introduction
Regulatory T-cells (Tregs) play a major role in immune homeostasis by preventing or limiting 
T-cell activation, particularly in the context of auto-antigens. Expression of the transcription fac-
tor forkhead box P3 (FOXP3), considered a master regulator of Treg development and function, is 
essential for their role in the maintenance of dominant tolerance [reviewed in Ref. (1)]. Conditions 
where FOXP3 is defective or absent, such as the recessive disorder immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked (IPEX) syndrome, are characterized by aggressive autoimmune 
manifestations that are usually fatal within the first 2 years of life, unless corrected via hematopoietic 
stem-cell transplantation (2–4).
Regulatory T-cells develop primarily in the thymus (thymus-derived Tregs, tTregs), although they 
can also be differentiated in the periphery (peripherally-induced Tregs). The delineation of these 
two populations in the peripheral Treg compartment is difficult due to the lack of specific markers. 
Nevertheless, tTregs are thought to be enriched in self-reactive T-cell receptors (TCRs) and to be 
critical for the maintenance of self-tolerance [reviewed in Ref. (1)]. Despite extensive research on 
tTreg development using murine models in the past 20 years, many questions remain unanswered 
regarding the mechanisms involved in the establishment and maintenance of the tTreg lineage 
[reviewed in Ref. (5, 6)]. Additionally, human tTreg studies are constrained by the limited number 
of tools available. Data have been mainly generated by in vitro manipulation of human thymic tissue 
or in vivo models using mouse/human chimeras [reviewed in Ref. (7)].
In this regard, the information provided by genetic human diseases characterized by thymus-
related disturbances, such as the DiGeorge, the Omenn, and the autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy (APECED) syndromes, have been instrumental [reviewed in 
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Ref. (8, 9)]. DiGeorge syndrome features athymia in <1% of the 
patients, but in the majority of them the prevailing thymic hypo-
plasia is associated with mild to moderate T-cell lymphopenia, 
and increased incidence of infection and autoimmune diseases 
[reviewed in Ref. (10)]. Alterations in the circulating Treg com-
partment have been consistently reported in DiGeorge syndrome 
(11–13). Notably, a decreased proportion and number of FOXP3+ 
cells in pediatric patients older than 2 years was observed when 
compared to age-matched healthy controls, in direct correlation 
with thymic output, as estimated by the numbers of CD4+ recent 
thymic emigrants (RTEs, defined by the expression of CD31 and 
CD45RA) (12). Omenn syndrome results from hypormorphic 
mutations in severe combined immunodeficiency (SCID)-
causing genes and is associated with the generation of a limited 
pool of T lymphocytes with a restricted repertoire and activated 
phenotype [reviewed in Ref. (8)]. Loss of corticomedullary 
junction and Hassall’s bodies with depletion of autoimmune 
regulator gene (AIRE)-expressing medullary thymic epithelial 
cells (mTECs) and thymic dendritic cells (DCs) were described in 
two Omenn patients, in parallel with a dramatic decrease of Tregs 
in the thymus (14), supporting a role of AIRE-expressing mTEC 
and/or thymic DCs in their differentiation. In agreement, loss-of-
function mutations in the AIRE gene (APECED syndrome) have 
been linked to a defective circulating Treg compartment (15–17). 
Not only is the frequency of naïve/resting Tregs (defined as CD4
+FOXP3+CD45ROnegCD31+) decreased in APECED patients but 
also their levels of FOXP3 expression, function, and repertoire are 
altered, further supporting an abnormal tTreg development in the 
absence of AIRE (16).
A recent study that involved a paired analysis of thymic and 
blood samples in young children (newborns to 1-year-old) 
showed a direct correlation between the size of the two Treg 
compartments, further supporting the importance of the thymus 
for the establishment of the peripheral Treg pool early in life 
(18). Of note, both human and murine RTEs are endowed with 
enhanced potential to convert into peripherally-induced Tregs, 
when compared to their more mature counterparts, implying an 
additional role of the thymus for the setting of the peripheral Treg 
compartment (19). Furthermore, patients with athymia due to 
complete DiGeorge or FOXN1 deficiency have been shown to 
recover the peripheral Treg compartment upon allogeneic thymus 
transplantation, irrespective of the degree of HLA mismatching 
(20–22).
It is vitally important to understand human tTreg development 
in order to devise strategies to manipulate their generation as well 
as their repertoire (23). This mini-review will provide an overview 
of the current knowledge regarding human tTreg development, as 
well as the fundamental questions that remain to be addressed.
Commitment to the Treg Lineage: when?
The human thymic primordium is colonized by T-cell progeni-
tors during the 8th week of gestation, but mature T-cells are only 
observed in the thymus at the 12th to 13th gestational weeks 
(24–26). At this stage, human tTregs can already be found in the 
thymus (27–29). The frequency of fetal human tTregs, identified 
by their elevated expression of the high-affinity IL-2 receptor 
alpha chain (IL-2Rα/CD25), was found to be stable throughout 
gestation (representing 6–7% of total thymocytes) and similar to 
the proportion observed in infant thymuses (28).
Fetal human tTregs already express FOXP3, as assessed at the 
gene expression level, as well as other markers related to their sup-
pressive phenotype, such as cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and glucocorticoid-induced TNFR-related 
protein (GITR) (27, 28). Moreover, these fetal human tTregs have 
the ability to suppress T-cell proliferation (27, 28).
One question that has been extensively addressed in mice, but 
due to technical limitations only in a few human studies, is when 
and how a thymocyte becomes committed to the Treg lineage. 
The discrete populations that express Treg markers, such as CD25 
and FOXP3, in the human post-natal thymus mainly comprise 
mature CD4 single-positive (CD4SP, CD4+CD8neg) thymocytes, 
but also include CD8 single-positive (CD8SP, CD4negCD8+) and 
double-positive (DP, CD4+CD8+) thymocytes, as well as cells 
in early pre-DP stages (27, 28, 30–36). In agreement, FOXP3+/
CD25+ thymocytes can be found mostly in the medullary region 
of the human thymus, where mature thymocytes localize, with 
rare cells scattered in the cortex (30, 31, 35, 37, 38). The mecha-
nisms that allow for human tTreg commitment to occur are still 
ill-defined.
We and others have reported pre-DP expression of FOXP3, 
namely, at the triple-negative and CD4 immature single-positive 
stages (33, 35) (Table 1). However, the contribution of this popu-
lation to the human tTreg pool remains to be addressed.
Double-positive thymocytes expressing FOXP3 and/or 
CD25 are clearly identified in the human thymus. They addi-
tionally express other Treg function-associated markers, such as 
CTLA-4, CD39, and GITR (27, 28, 36), and exhibit suppressive 
function (32, 36) (Table 1). DP tTregs feature some degree of 
immaturity, as evidenced by the expression of recombination-
activating gene 2 mRNA (34). Moreover, upon stripping of 
surface molecules using pronase, DP tTregs re-acquire both 
CD4 and CD8 at the surface, confirming their bona-fide DP 
status (36). Nevertheless, the majority of human DP tTregs 
express high levels of CD3 and CD27, which are associated with 
positive selection and maturity (27, 36) (Table 1). Importantly, 
DP tTregs are thought to significantly contribute to the CD4SP 
tTreg pool in humans, as predicted by linear regression models 
(36), and formally demonstrated by co-cultures of DP thymo-
cytes with either TEC (36) or mature plasmacytoid (p)DCs 
(38). This observation contrasts with what has been described 
in murine models, where Foxp3 induction, although possible at 
the DP stage (45–47), mostly occurs at the CD4SP stage (48). Of 
note, human CD4SP CD25neg thymocytes are also permissive to 
FOXP3 acquisition (37, 39, 49).
CD4SP tTreg represent the major population of FOXP3+ 
human thymocytes. They phenotypically mirror peripheral 
Tregs and exhibit efficient regulatory function (27, 28, 30, 36, 
41, 43) (Table 1). The contribution of recirculating peripheral 
Tregs to this tTreg compartment is still debatable. It has long 
been proposed that activated T-cells may recirculate back to the 
thymus (50, 51), although this issue is particularly difficult to 
assess in humans. Recently, it was reported that a considerable 
proportion of human CD4SP tTregs may consist of recirculating 
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cells (44). This was based on the observation that approximately 
one-fourth of these cells had lost CD31 and acquired ICOS 
and Tbet expression. Although it is not possible to exclude 
that a fraction of human tTregs may actually represent mature 
recirculating cells, there are some caveats to this interpretation. 
For instance, ICOS is already expressed by tTreg at the DP stage 
(39). Also, the high FOXP3 expression levels found within 
CD4SP ICOS+CD31neg tTregs (44) may reflect their interaction 
with ICOSL expressed on mTECs, as previously described (52). 
Moreover, TREC levels are reportedly comparable between the 
CD4SP CD25+ and CD25neg thymocyte populations, and several 
logs higher that those found in circulating Tregs, supporting that 
the majority of CD4SP tTregs are at the final stage of T-cell devel-
opment (53). Of note, Vbeta usage and spectratyping analyses 
supported that CD4SP tTregs and CD4SP FOXP3neg/CD25neg 
thymocytes have a similarly diverse repertoire (36, 53). To our 
knowledge, the direct comparison of the thymic CD4SP FOXP3+ 
and FOXP3neg repertoires has not been reported. Its assessment 
will be important to clarify this issue since in peripheral cells 
the Treg repertoire has only 24% overlap with conventional CD4 
T-cells (54). Additional studies will be instrumental in deter-
mining the magnitude and role of mature Treg recirculation in 
the human thymus.
Thus, tTreg lineage commitment may occur at various stages 
of human T-cell development.
Commitment to the Treg Lineage: How?
Studies in mice have clearly established the requirement for 
TCR stimulation in Treg lineage commitment [reviewed in 
Ref. (5, 6)]. In humans, technical limitations preclude a direct 
assessment of the role of TCR signaling in tTreg development. 
We and others have shown that human tTreg differentiation 
is associated with markers of positive selection, such as CD69 
and CD27 (27, 28, 34, 36, 42) (Table 1). Moreover, binding sites 
for the TCR downstream targets NFAT and AP1 are present 
within the human FOXP3 promoter that are directly activated 
by TCR stimulation (55). Notably, both DP and CD4SP tTreg 
express CTLA-4 (30, 36), a molecule that in mice was shown to 
be downstream of Nur77, an immediate early gene upregulated 
TABLe 1 | Characterization of human post-natal thymic Tregs.
Markers Pre-DP DP CD4SP CD8SP Reference
FOXP3 + +++ +++ ++ (31, 33, 35, 36, 39, 40)
CD25 − +++ +++ ++ (30, 31, 33, 35, 36, 39, 41)
CTLA-4 + +++ +++ ++ (30, 31, 33, 36, 39, 41, 42)
CD127 −/+ + − − (33–36)
HLA-DR ND ++ + + (36)
CD39 ND ++ ++ + (36)
CD73 ND − − + (36)
CD103 ND + − ++ (36)
ICOS ND ++ ++ + (39, 43, 44)
CD69 ND ++ ++ + (34, 36, 42)
CD27 ND ++ ++ ++ (36, 42)
Ki67 + + −/+ −/+ (36)
Suppressive 
capacity
ND Yes Yes Yes (30–32, 36, 39, 41)
ND, not determined.
by TCR stimulation (56). Indirect evidence that enhanced TCR 
signaling strength may dictate thymocyte commitment into the 
Treg lineage can be further inferred by the increase in CD4SP 
CD25+FOXP3+ thymocyte number in humanized mice treated 
with a superagonist anti-CD28 mAb (57). Moreover, human 
ZAP70-deficient patients present a dramatic decrease in the 
frequency and number of tTregs (58). Interestingly, CD4SP 
CD25+ tTregs were shown to frequently express two functional 
TCRs, in association with enhanced FOXP3 expression, suggest-
ing that dual TCR expression may favor tTreg lineage commit-
ment in humans (40). Overall, available evidence support that 
TCR signaling strength guides thymocyte commitment into 
the Treg lineage in humans, with a predicted impact on their 
self-reactivity.
Several additional signaling pathways and molecular fac-
tors have been implicated in human tTreg differentiation and/
or proliferation, namely JAK3/STAT-5, Notch, CD80/CD86, 
ICOS/ICOSL, CD40/CD40L, thymic stromal lymphopoietin 
(TSLP), as well as the common-gamma chain (γC) cytokines 
interleukin (IL)-2 and -15 (37–39, 49, 52, 59). Watanabe et al. 
demonstrated that TSLP from Hassall’s bodies activate myeloid 
(m)DCs, enabling them to induce tTreg differentiation from 
CD4SP CD25neg thymocytes (37). pDCs are also capable of 
driving CD4SP non-regulatory thymocytes into the human 
Treg lineage, upon response to TSLP (49). Cognate interactions 
between mDCs or pDCs and CD4SP non-regulatory thymo-
cytes are required, as differentiation was impaired by HLA-DR 
blockade (37, 49). Activation of pDCs with anti-CD40L and 
IL-3 also confers on them the capacity to differentiate post-
selection DP CD69hiTCRhi thymocytes into human tTregs (38). 
Additionally, mTECs were shown to promote the survival 
and proliferation of human tTregs in an ICOSL-dependent 
mechanism that required the presence of conventional CD4SP 
cells as source of IL-2 (52). We have recently investigated the 
requirement of γC cytokines in human tTreg development and 
established a critical role for both IL-2 and IL-15 in their line-
age commitment, as well as in tTreg proliferation and survival 
post-selection (39). This study also allowed the identification 
of macrophages and B lymphocytes as main IL-15 producers 
that likely represent two additional thymic antigen-presenting 
cell populations involved in human tTreg differentiation 
(39). In agreement, we found FOXP3+ cells in close vicinity 
of both macrophages and B cells in the human thymus (39). 
Accordingly, B lymphocytes were recently shown to be capable 
of selecting tTreg in mice (60, 61), and the majority of human 
CD4SP tTregs were shown to express CCR8 endowing them 
with the capacity to migrate in response to chemokines pro-
duced by macrophages (30).
As illustrated in Figure  1, the most immature thymocyte 
population that clearly expresses FOXP3, in addition to other 
Treg function-associated markers, such as CD25, CTLA-4, 
and CD39, and displays regulatory function is the cortical 
positively selected DP population (27, 28, 36). The thymic cel-
lular populations and signals mediating their positive selection 
and concomitant recruitment to the Treg lineage may include 
cortical TECs and macrophages, as well as IL-2/IL-15, shown 
by immunohistochemistry to be expressed in the human thymic 
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cortex (39). The DP FOXP3+ thymocyte compartment directly 
correlates with the CD4SP FOXP3+ subset, denoting a precur-
sor–product relationship (36). Upon interaction with activated 
pDCs, post-selection DP FOXP3neg cells may also differentiate 
into Tregs, in a costimulation-dependent manner (38). Medullary 
CD4SP FOXP3neg thymocytes can also acquire FOXP3 expression 
upon cognate interaction with activated pDCs or mDCs, in a 
costimulation- and IL-2-dependent fashion (37, 49). In addition, 
CD4SP FOXP3neg thymocytes may receive appropriate TCR and 
costimulation signals leading to CD25 acquisition and differen-
tiation into tTreg precursors (CD4SP CD25+FOXP3neg cells) (39). 
These precursors can differentiate into tTregs upon exposure to 
IL-2, produced mostly by cycling mature CD4SP thymocytes, or 
IL-15 secreted by macrophages, B lymphocytes, or mTECs (39). 
Whether concomitant TCR, costimulation, and γC cytokine 
signaling also commits medullary CD4SP FOXP3neg thymocytes 
into tTregs, is a possibility remaining to be addressed. Finally, 
CD4SP CD25negFOXP3neg thymocytes TCR-stimulated in the 
presence of costimulation, TGF-β and IL-2/IL-15 signaling can 
also acquire FOXP3 expression and differentiate into CD4SP 
tTreg (19, 39).
FiGURe 1 | Schematic representation of human Treg development 
in the human thymus. DP, double-positive (CD4+CD8+); CD4SP, 
CD4 single-positive (CD4+CD8neg); CD8SP, CD8 single-positive 
(CD8+CD4neg); cTEC, cortical thymic epithelial cell; mTEC, medullary TEC; 
Mac, macrophage; FOXP3, Forkhead box P3; TSLP, thymic stromal 
lymphopoietin.
The Unique Properties of Human  
CD8SP tTregs
In addition to the CD4SP human tTregs, a CD8SP population 
with phenotypic and functional Treg characteristics is present in 
the human thymus. CD8SP human tTregs express several Treg-
associated markers, such as FOXP3, CD25, CTLA-4, and GITR, 
although at lower levels than CD4SP tTregs (31, 36) (Table 1). 
Similarly to CD4SP tTregs, they express very low levels of the 
IL-7 Rα/CD127 molecule (36), and are able to suppress CD4SP 
CD25neg cells in a contact-dependent manner (31) (Table 1). A 
microRNA “signature” of CD8 Tregs has been recently defined in 
cord blood CD8 Treg (62).
Importantly, CD8SP human tTregs were found to express the 
αE chain (CD103) of the αEβ7 integrin (36), a marker associated 
with CD4 Tregs in the periphery (63). CD103 was also expressed 
at the DP stage but was very low within CD4SP thymocytes, sup-
porting a precursor–product relationship between CD103+ DP 
and CD8SP human tTregs (36) (Table 1; Figure 1).
The role of CD103 expression on CD8SP FOXP3+ thymocytes 
remains to be addressed. High expression of E-cadherin, the 
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main ligand of CD103, on mTEC (64) may promote retention of 
CD8 tTregs in the thymic medulla. Furthermore, in an in vitro 
cell adhesion assay, TEC-induced proliferation of CD8SP human 
thymocytes was inhibited by antibodies against E-cadherin or 
CD103, supporting a role for CD103 in CD8SP proliferation 
(64). Although the proliferation of CD8SP CD25+ thymocytes 
was not addressed in this setting, the higher levels of the active 
cell-cycle marker Ki67 found within CD8SP FOXP3+ as com-
pared to CD8SP FOXP3neg thymocytes (36) also support this 
hypothesis.
Despite the low frequency of CD8+ Treg in the steady state, they 
may be of special relevance in pathologic conditions [reviewed in 
Ref. (65, 66)]. CD103 has been associated with T-cell migration 
to mucosal sites (67, 68). In agreement, in the setting of colorectal 
cancer, CD8+FOXP3+CD25+ T-cells were significantly increased 
in peripheral blood and in colorectal cancer tissue, indicating that 
these cells may contribute to tumor immune escape and disease 
progression (69). In addition, studies in macaques have described 
a rapid expansion of CD8+FOXP3+CD25+ Tregs in the blood and 
colorectal mucosa following pathogenic SIV infection (70). An 
increase in the frequency of CD8+ Tregs has also been reported 
in HIV-1-infected patients (70).
In conclusion, a population of CD8+ Tregs is generated in the 
human thymus. A subset of post-selection DP FOXP3+ thymo-
cytes expresses the tissue homing-associated molecule CD103, 
likely giving rise to the CD8SP FOXP3+CD103+ cells found in 
the medulla (Figure 1) (36). This finding supports the possibility 
that CD8+ Tregs egress the thymus expressing markers associ-
ated with mucosal homing, which may explain their very low 
frequency in the blood.
Concluding Remarks
Cumulative evidence supports the existence of different pathways 
of Treg commitment in the human thymus that may occur at 
different stages of thymocyte differentiation. Their physiological 
contribution and the possible implications for the tTreg repertoire 
diversity remain unclear.
Thymus-derived Treg development does not seem to require a 
dedicated antigen-presenting cell population, as studies indicate 
that TECs, mDC, and pDC, as well as macrophages and B cells 
may be involved in tTreg selection. Finally, despite the proposed 
role of TCR signaling strength in human tTreg commitment, it 
has become increasingly clear that γC cytokines, particularly IL-2 
and IL-15, are important mediators of lineage stabilization.
The thymus and specifically tTregs represent important thera-
peutic targets to manipulate tolerance in many clinical settings, 
namely autoimmune diseases, tumor immunity, and transplan-
tation. Furthermore, their targeting is also critical to achieve 
full immunological reconstitution in primary and secondary 
immunodeficiencies and to decrease the morbidity associated 
with hematopoietic stem-cell transplantation. It is therefore of 
utmost importance to further investigate human tTreg develop-
ment, in order to take full-advantage of the current development 
of immune-based therapies.
Acknowledgments
IC, HN-C, and RBF received scholarships from Fundação para a 
Ciência e a Tecnologia (FCT) cofinanced by Programa Operacional 
Ciência e Inovação 2010 (POCI2010).
References
 1. Sakaguchi S, Miyara M, Constantino CM, Hafler DA. FOXP3+ regulatory 
T cells in the human immune system. Nat Rev Immunol (2010) 10:490–500. 
doi:10.1038/nri2785 
 2. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, 
et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27:20–1. 
doi:10.1038/83713 
 3. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked 
neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the 
human equivalent of mouse scurfy. Nat Genet (2001) 27:18–20. doi:10.1038/83707 
 4. Seidel MG, Fritsch G, Lion T, Jurgens B, Heitger A, Bacchetta R, et al. Selective 
engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome 
after nonmyeloablative hematopoietic stem cell transplantation. Blood (2009) 
113:5689–91. doi:10.1182/blood-2009-02-206359 
 5. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T Cells: mechanisms of dif-
ferentiation and function. Annu Rev Immunol (2012) 30:531–64. doi:10.1146/
annurev.immunol.25.022106.141623 
 6. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat 
Rev Immunol (2012) 12:157–67. doi:10.1038/nri3155 
 7. Legrand N, Weijer K, Spits H. Experimental models to study development and 
function of the human immune system in vivo. J Immunol (2006) 176:2053–8. 
doi:10.4049/jimmunol.176.4.2053 
 8. Notarangelo LD. Combined immunodeficiencies with nonfunctional T lym-
phocytes. Adv Immunol (2014) 121:121–90. doi:10.1016/B978-0-12-800100-4. 
00004-0 
 9. Pignata C, D’Assante R, Sousa AE. Thymic stromal alterations and genetic 
disorders of immune system. Front Immunol (2015) 6:81. doi:10.3389/
fimmu.2015.00081 
 10. Davies EG. Immunodeficiency in DiGeorge syndrome and options for treat-
ing cases with complete athymia. Front Immunol (2013) 4:322. doi:10.3389/
fimmu.2013.00322 
 11. Sullivan KE, McDonald-McGinn D, Zackai EH. CD4(+) CD25(+) T-cell 
production in healthy humans and in patients with thymic hypoplasia. Clin 
Diagn Lab Immunol (2002) 9:1129–31. doi:10.1128/CDLI.9.5.1129-1131.2002 
 12. McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Immunologic defects in 
22q11.2 deletion syndrome. J Allergy Clin Immunol (2008) 122:e–7. doi:10.1016/ 
j.jaci.2008.03.033 
 13. Klocperk A, Grecová J, Šišmová K, Kayserová J, Froňková E, Šedivá A. Helios 
expression in T-regulatory cells in patients with Di George syndrome. J Clin 
Immunol (2014) 34:864–70. doi:10.1007/s10875-014-0071-y 
 14. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, 
et al. Early defects in human T-cell development severely affect distribution 
and maturation of thymic stromal cells: possible implications for the patho-
physiology of Omenn syndrome. Blood (2009) 114:105–8. doi:10.1182/
blood-2009-03-211029 
 15. Kekalainen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, Pontynen N, 
et al. A defect of regulatory T cells in patients with autoimmune polyendocr-
inopathy-candidiasis-ectodermal dystrophy. J Immunol (2007) 178:1208–15. 
doi:10.4049/jimmunol.178.2.1208 
 16. Laakso SM, Laurinolli TT, Rossi LH, Lehtoviita A, Sairanen H, Perheentupa 
J, et al. Regulatory T cell defect in APECED patients is associated with loss of 
naive FOXP3(+) precursors and impaired activated population. J Autoimmun 
(2010) 35:351–7. doi:10.1016/j.jaut.2010.07.008 
 17. Arstila TP, Jarva H. Human APECED; a sick thymus syndrome? Front Immunol 
(2013) 4:313. doi:10.3389/fimmu.2013.00313 
 18. Machnes-Maayan D, Lev A, Katz U, Mishali D, Vardi A, Simon AJ, et  al. 
Insight into normal thymic activity by assessment of peripheral blood samples. 
Immunol Res (2015) 61:198–205. doi:10.1007/s12026-014-8558-4 
August 2015 | Volume 6 | Article 3956
Caramalho et al. Human thymic Treg development
Frontiers in Immunology | www.frontiersin.org
 19. Paiva RS, Lino AC, Bergman ML, Caramalho I, Sousa AE, Zelenay S, et al. 
Recent thymic emigrants are the preferential precursors of regulatory T cells 
differentiated in the periphery. Proc Natl Acad Sci U S A (2013) 110:6494–9. 
doi:10.1073/pnas.1221955110 
 20. Markert ML, Marques JG, Neven B, Devlin BH, McCarthy EA, Chinn IK, 
et  al. First use of thymus transplantation therapy for FOXN1 deficiency 
(nude/SCID): a report of 2 cases. Blood (2011) 117:688–96. doi:10.1182/
blood-2010-06-292490 
 21. Albuquerque AS, Marques JG, Silva SL, Ligeiro D, Devlin BH, Dutrieux J, et al. 
Human FOXN1-deficiency is associated with αβ double-negative and FoxP3+ 
T-cell expansions that are distinctly modulated upon thymic transplantation. 
PLoS One (2012) 7:e37042. doi:10.1371/journal.pone.0037042.g005 
 22. Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus trans-
plantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and 
FoxP3− T cells in complete DiGeorge anomaly. Clin Exp Immunol (2013) 
173:140–9. doi:10.1111/cei.12088 
 23. Nunes-Cabaço H, Sousa AE. Repairing thymic function. Curr Opin Organ 
Transplant (2013) 18:363–8. doi:10.1097/MOT.0b013e3283615df9 
 24. Haynes BF, Heinly CS. Early human T cell development: analysis of the human 
thymus at the time of initial entry of hematopoietic stem cells into the fetal 
thymic microenvironment. J Exp Med (1995) 181:1445–58. doi:10.1084/
jem.181.4.1445 
 25. Farley AM, Morris LX, Vroegindeweij E, Depreter MLG, Vaidya H, Stenhouse 
FH, et al. Dynamics of thymus organogenesis and colonization in early human 
development. Development (2013) 140:2015–26. doi:10.1242/dev.087320 
 26. Haddad R, Guimiot F, Six E, Jourquin F, Setterblad N, Kahn E, et al. Dynamics 
of thymus-colonizing cells during human development. Immunity (2006) 
24:217–30. doi:10.1016/j.immuni.2006.01.008 
 27. Cupedo T, Nagasawa M, Weijer K, Blom B, Spits H. Development and activa-
tion of regulatory T cells in the human fetus. Eur J Immunol (2005) 35:383–90. 
doi:10.1002/eji.200425763 
 28. Darrasse-Jèze G, Marodon G, Salomon BL, Catala M, Klatzmann D. Ontogeny 
of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood (2005) 
105:4715–21. doi:10.1182/blood-2004-10-4051 
 29. Michaelsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses 
in the developing human fetus. J Immunol (2006) 176:5741–8. doi:10.4049/
jimmunol.176.10.5741 
 30. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, et  al. 
Phenotype, localization, and mechanism of suppression of CD4+CD25+ 
human thymocytes. J Exp Med (2002) 196:379–87. doi:10.1084/jem.20020110 
 31. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et  al. 
Human CD8+CD25+ thymocytes share phenotypic and functional features 
with CD4+CD25+ regulatory thymocytes. Blood (2003) 102:4107–14. 
doi:10.1182/blood-2003-04-1320 
 32. Liotta F, Cosmi L, Romagnani P, Maggi E, Romagnani S, Annunziato F. 
Functional features of human CD25+ regulatory thymocytes. Microbes Infect 
(2005) 7:1017–22. doi:10.1016/j.micinf.2005.03.024 
 33. Tuovinen H, Kekäläinen E, Rossi LH, Puntila J, Arstila TP. Cutting edge: 
human CD4−CD8− thymocytes express FOXP3 in the absence of a TCR. 
J Immunol (2008) 180:3651–4. doi:10.4049/jimmunol.180.6.3651 
 34. Tuovinen H, Pekkarinen PT, Rossi LH, Mattila I, Arstila TP. The FOXP3+ sub-
set of human CD4+CD8+ thymocytes is immature and subject to intrathymic 
selection. Immunol Cell Biol (2008) 86:523–9. doi:10.1038/icb.2008.36 
 35. Nunes-Cabaço H, Ribot JC, Caramalho Í, Serra-Caetano A, Silva-Santos B, 
Sousa AE. Foxp3 induction in human and murine thymus precedes the CD4+ 
CD8+ stage but requires early T-cell receptor expression. Immunol Cell Biol 
(2010) 88:523–8. doi:10.1038/icb.2010.4 
 36. Nunes-Cabaço H, Caramalho Í, Sepúlveda N, Sousa AE. Differentiation of 
human thymic regulatory T cells at the double positive stage. Eur J Immunol 
(2011) 41:3604–14. doi:10.1002/eji.201141614 
 37. Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, Cao W, et  al. Hassall’s 
corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells 
in human thymus. Nature (2005) 436:1181–5. doi:10.1038/nature03886 
 38. Martin-Gayo E, Sierra-Filardi E, Corbi AL, Toribio ML. Plasmacytoid den-
dritic cells resident in human thymus drive natural Treg cell development. 
Blood (2010) 115:5366–75. doi:10.1182/blood-2009-10-248260 
 39. Caramalho Í, Nunes-Silva V, Pires AR, Mota C, Pinto AI, Nunes-Cabaço 
H, et  al. Human regulatory T-cell development is dictated by interleukin-2 
and -15 expressed in a non-overlapping pattern in the thymus. J Autoimmun 
(2015) 56:98–110. doi:10.1016/j.jaut.2014.11.002 
 40. Tuovinen H, Salminen JT, Arstila TP. Most human thymic and peripheral-blood 
CD4+CD25+ regulatory T cells express 2 T-cell receptors. Blood (2006) 
108:4063–70. doi:10.1182/blood-2006-04-016105 
 41. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4+ CD25+ thymo-
cytes and peripheral T cells have immune suppressive activity in vitro. Eur 
J Immunol (2001) 31:1247–54. doi:10.1002/1521-4141(200104)31:4<1247:: 
AID-IMMU1247>3.0.CO;2-M 
 42. Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of 
human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology 
(2002) 106:190–9. doi:10.1046/j.1365-2567.2002.01412.x 
 43. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, et al. Two func-
tional subsets of FOXP3+ regulatory T cells in human thymus and periphery. 
Immunity (2008) 28:870–80. doi:10.1016/j.immuni.2008.03.018 
 44. Thiault N, Darrigues J, Adoue V, Gros M, Binet B, Perals C, et al. Peripheral 
regulatory T lymphocytes recirculating to the thymus suppress the develop-
ment of their precursors. Nat Immunol (2015) 16:628–34. doi:10.1038/ni.3150 
 45. Cabarrocas J, Cassan C, Magnusson F, Piaggio E, Mars L, Derbinski J, et al. 
Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at 
the double-positive thymic stage. Proc Natl Acad Sci U S A (2006) 103:8453–8. 
doi:10.1073/pnas.0603086103 
 46. Ribot J, Enault G, Pilipenko S, Huchenq A, Calise M, Hudrisier D, et al. Shaping 
of the autoreactive regulatory T cell repertoire by thymic cortical positive 
selection. J Immunol (2007) 179:6741–8. doi:10.4049/jimmunol.179.10.6741 
 47. Liston A, Nutsch KM, Farr AG, Lund JM, Rasmussen JP, Koni PA, et  al. 
Differentiation of regulatory Foxp3+ T cells in the thymic cortex. Proc Natl 
Acad Sci U S A (2008) 105:11903–8. doi:10.1073/pnas.0801506105 
 48. Lee HM, Hsieh CS. Rare development of Foxp3+ thymocytes in the CD4+CD8+ 
subset. J Immunol (2009) 183:2261–6. doi:10.4049/jimmunol.0901304 
 49. Hanabuchi S, Ito T, Park WR, Watanabe N, Shaw JL, Roman E, et al. Thymic 
stromal lymphopoietin-activated plasmacytoid dendritic cells induce the 
generation of FOXP3+ regulatory T cells in human thymus. J Immunol (2010) 
184:2999–3007. doi:10.4049/jimmunol.0804106 
 50. Michie SA, Rouse RV. Traffic of mature lymphocytes into the mouse thymus. 
Thymus (1989) 13:141–8. 
 51. Kirberg J, Bosco N, Deloulme JC, Ceredig R, Agenès F. Peripheral T lym-
phocytes recirculating back into the thymus can mediate thymocyte positive 
selection. J Immunol (2008) 181:1207–14. doi:10.4049/jimmunol.181.2.1207 
 52. Nazzal D, Gradolatto A, Truffault F, Bismuth J, Berrih-Aknin S. Human thymus 
medullary epithelial cells promote regulatory T-cell generation by stimulating 
interleukin-2 production via ICOS ligand. Cell Death Dis (2014) 5:e1420. 
doi:10.1038/cddis.2014.377 
 53. Kasow KA, Chen XH, Knowles J, Wichlan D, Handgretinger R, Riberdy JM. 
Human CD4+CD25+ regulatory T cells share equally complex and compara-
ble repertoires with CD4+CD25- counterparts. J Immunol (2004) 172:6123–8. 
doi:10.4049/jimmunol.172.10.6123 
 54. Fazilleau N, Bachelez H, Gougeon ML, Viguier M. Cutting edge: size and 
diversity of CD4+CD25high Foxp3+ regulatory T cell repertoire in humans: 
evidence for similarities and partial overlapping with CD4+CD25- T Cells. 
J Immunol (2007) 179:3412–6. doi:10.4049/jimmunol.179.6.3412 
 55. Mantel PY, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K, et al. 
Molecular mechanisms underlying FOXP3 induction in human T cells. 
J Immunol (2006) 176:3593–602. doi:10.4049/jimmunol.176.6.3593 
 56. Rajpal A, Cho YA, Yelent B, Koza-Taylor PH, Li D, Chen E, et al. Transcriptional 
activation of known and novel apoptotic pathways by Nur77 orphan steroid 
receptor. EMBO J (2003) 22:6526–36. doi:10.1093/emboj/cdg620 
 57. Legrand N, Cupedo T, van Lent AU, Ebeli MJ, Weijer K, Hanke T, et  al. 
Transient accumulation of human mature thymocytes and regulatory T cells 
with CD28 superagonist in “human immune system” Rag2-/-gammac-/- mice. 
Blood (2006) 108:238–45. doi:10.1182/blood-2006-01-0190 
 58. Poliani PL, Fontana E, Roifman CM, Notarangelo LD. ζ Chain-associated pro-
tein of 70 kDa (ZAP70) deficiency in human subjects is associated with abnor-
malities of thymic stromal cells: implications for T-cell tolerance. J Allergy Clin 
Immunol (2013) 131:e–600. doi:10.1016/j.jaci.2012.11.002 
 59. Hutton JF, Gargett T, Sadlon TJ, Bresatz S, Brown CY, Zola H, et al. Development 
of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic 
progenitor cells. J Leukoc Biol (2008) 85:445–51. doi:10.1189/jlb.1008620 
August 2015 | Volume 6 | Article 3957
Caramalho et al. Human thymic Treg development
Frontiers in Immunology | www.frontiersin.org
 60. Walters SN, Webster KE, Daley S, Grey ST. A role for intrathymic B cells in 
the generation of natural regulatory T cells. J Immunol (2014) 193:170–6. 
doi:10.4049/jimmunol.1302519 
 61. Lu FT, Yang W, Wang YH, Ma HD, Tang W, Yang JB, et  al. Thymic B cells 
promote thymus-derived regulatory T cell development and proliferation. 
J Autoimmun (2015) 61:62–72. doi:10.1016/j.jaut.2015.05.008 
 62. Jebbawi F, Fayyad-Kazan H, Merimi M, Lewalle P, Verougstraete JC, Leo O, 
et al. A microRNA profile of human CD8(+) regulatory T cells and character-
ization of the effects of microRNAs on Treg cell-associated genes. J Transl Med 
(2014) 12:218. doi:10.1186/s12967-014-0218-x 
 63. Allakhverdi Z, Fitzpatrick D, Boisvert A, Baba N, Bouguermouh S, Sarfati M, 
et al. Expression of CD103 identifies human regulatory T-cell subsets. J Allergy 
Clin Immunol (2006) 118:1342–9. doi:10.1016/j.jaci.2006.07.034 
 64. Kutlesa S, Wessels JT, Speiser A, Steiert I, Müller CA, Klein G. E-cadherin-
mediated interactions of thymic epithelial cells with CD103+ thymocytes 
lead to enhanced thymocyte cell proliferation. J Cell Sci (2002) 115:4505–15. 
doi:10.1242/jcs.00142 
 65. Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 
T cells. Cell Mol Immunol (2005) 2:11–19. 
 66. Kapp JA, Bucy RP. CD8+ suppressor T cells resurrected. Hum Immunol (2008) 
69:715–20. doi:10.1016/j.humimm.2008.07.018 
 67. Cerf-Bensussan N, Jarry A, Brousse N, Lisowska-Grospierre B, Guy-Grand 
D, Griscelli C. A monoclonal antibody (HML-1) defining a novel membrane 
molecule present on human intestinal lymphocytes. Eur J Immunol (1987) 
17:1279–85. doi:10.1002/eji.1830170910 
 68. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates 
adhesion of T lymphocytes to epithelial cells. J Immunol (1993) 150:3459–70. 
 69. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F, et  al. 
Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer 
tissue. Gut (2009) 58:520–9. doi:10.1136/gut.2008.158824 
 70. Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, Siddiqui M, et al. 
Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal 
mucosa following a pathogenic simian immunodeficiency virus infection cor-
relates with diminished antiviral T cell response and viral control. J Immunol 
(2010) 184:1690–701. doi:10.4049/jimmunol.0902955 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Caramalho, Nunes-Cabaço, Foxall and Sousa. This is an open-ac-
cess article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
